Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro , Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo
Published version of a preprint
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: We compared the efficacy of human Langerhans cells (LC) as tumor immunogens in vivo with monocyte-derived dendritic cells (moDC) and investigated how interleukin 15 (IL15) supports optimal DC-stimulated antitumor immunity. Experimental Design: American Joint Committee on Cancer stage III/IV melanoma patients participated in this first clinical trial comparing melanoma peptide-pulsed LC with moDC vaccines (NCT00700167, www.ClinicalTrials.gov). Correlative studies evaluated mechanisms mediating IL15 support of DC-stimulated antitumor immunity. Results: Both DC vaccines were safe and immunogenic for melanoma antigens. LC-based vaccines stimulated significantly greater tyrosinase–HLA-A*0201 tetramer reactivity than the moDC-based vaccines. The two DC subtypes were otherwise statistically comparable, in contrast to extensive prior data in vitro showing LC superiority. LCs synthesize much more IL15 than moDCs and stimulate significantly more antigen-specific lymphocytes with a cytolytic IFN-γ profile even without exogenous IL15. When supplemented by low-dose IL15, instead of IL2, moDCs stimulate 5 to 6 logs more tumor antigen–specific effector memory T cells (TEMRA) over 3 to 4 weeks in vitro. IL2 and IL15 can be synergistic in moDC stimulation of cytolytic T cells. IL15 promotes T-cell expression of the antiapoptotic bcl-2 and inhibits candidate regulatory T-cell (Treg) expansion after DC stimulation, countering two effects of IL2 that do not foster tumor immunity. Conclusions: MoDC-based vaccines will require exogenous IL15 to achieve clinical efficacy. Alternatively, LCs can couple the endogenous production of IL15 with potent T-cell stimulatory activity. Optimization of full-length tumor antigen expression for processing into multiple immunogenic peptides for presentation by both class I and II MHC therefore merits emphasis to support more effective antitumor immunity stimulated by LCs. Clin Cancer Res; 17(7); 1984–97. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mRNA electroporation also allows individuals of any HLA type to process and present peptides tailored to their own MHC molecules.”
In the citing paper
“This method of antigen loading, which facilitates processing and presentation of multiple class I and II MHC-restricted epitopes from the translated protein [12], is more efficient than peptide pulsing and less problematic than retroviral transgenes, which carry the risk of genome integration [13].”
In the citing paper
“Although patients treated on the LC arm of our trial generated significantly greater reactivity against tyrosinase than those treated with moDCs, significant differences were not observed for gp100 or the control fluMP antigen [12].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Interleukin 15: biology and relevance to human disease
Fehniger, T. A., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.1.14 · Cited by 976
Migratory properties of naive, effector, and memory CD8(+) T cells
Weninger, W., Crowley, M. A., Manjunath, N., & von Andrian, U. H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.953 · Cited by 515
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes
Romero, P., Zippelius, A., Kurth, I., Pittet, M. J., Touvrey, C., Iancu, E. M., Corthesy, P., Devevre, E., Speiser, D. E., & Rufer, N. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4112 · Cited by 405
Rufer, N., Zippelius, A., Batard, P., Pittet, M. J., Kurth, I., Corthesy, P., Cerottini, J.-C., Leyvraz, S., Roosnek, E., Nabholz, M., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0420 · Cited by 182
Research works printed but not linked: 32
- Ratzinger, 2004, Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol, (Erratum in J Immunol, 173, 2780, 10.4049/jimmunol.173.4.2780 · DOI · Paper page
- Klechevsky, 2008, Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells, Immunity, 29, 497, 10.1016/j.immuni.2008.07.013 · DOI · Paper page
- Banchereau, 2001, Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine, Cancer Res, 61, 6451
- Munz, 2005, Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells, Blood, 105, 266, 10.1182/blood-2004-06-2492 · DOI
- Waldmann, 2006, The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design, Nat Rev Immunol, 6, 595, 10.1038/nri1901 · DOI · Paper page
- Klebanoff, 2005, Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells, Proc Natl Acad Sci U S A, 102, 9571, 10.1073/pnas.0503726102 · DOI · Paper page
- Mueller, 2003, IL-15 enhances survival and function of HIV-specific CD8+ T cells, Blood, 101, 1024, 10.1182/blood-2002-07-1957 · DOI
- Oh, 2004, IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells, Proc Natl Acad Sci U S A, 101, 15154, 10.1073/pnas.0406649101 · DOI
- Stonier, 2008, Dendritic cells drive memory CD8 T cell homeostasis via IL-15 trans-presentation, Blood, 112, 4546, 10.1182/blood-2008-05-156307 · DOI · Paper page
- Dubois, 2005, Survival adjustment of mature dendritic cells by IL-15. Proceedings of the National Academy of Sciences of the United States of America, 102, 8662
- Berger, 2009, Safety and immunologic effects of IL-15 administration in nonhuman primates, Blood, 114, 2417, 10.1182/blood-2008-12-189266 · DOI · Paper page
- Banchereau, 2005, Dendritic cells as therapeutic vaccines against cancer, Nat Rev Immunol, 5, 296, 10.1038/nri1592 · DOI · Paper page
- Mohamadzadeh, 2001, Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells, J Exp Med, 194, 1013, 10.1084/jem.194.7.1013 · DOI
- Dubsky, 2007, IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL, Eur J Immunol, 37, 1678, 10.1002/eji.200636329 · DOI
- Ratzinger, 2005, Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells, J Immunol, 174, 3818, 10.4049/jimmunol.174.6.3818 · doi:10.4049/jimmunol.174.6.3818
- Szabolcs, 1995, Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α, J Immunol, 154, 5851, 10.4049/jimmunol.154.11.5851 · DOI · Paper page
- Szabolcs, 1996, Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate, Blood, 87, 4520, 10.1182/blood.V87.11.4520.bloodjournal87114520 · DOI · Paper page
- Maecker, 2005, Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT, BMC Immunol, 6, 17, 10.1186/1471-2172-6-17 · DOI
- Young, 1993, High dose UV-B radiation alters dendritic cell costimulatory activity but does not tolerize T lymphocytes to alloantigen in vitro, Blood, 81, 2987, 10.1182/blood.V81.11.2987.2987 · DOI
- Sallusto, 1999, Two subsets of memory T lymphocytes with distinct homing potentials and effector functions, Nature, 401, 708, 10.1038/44385 · DOI · Paper page
- Williams, 2006, Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells, Nature, 441, 890, 10.1038/nature04790 · DOI · Paper page
- Williams, 2007, Effector and memory CTL differentiation, Annu Rev Immunol, 25, 171, 10.1146/annurev.immunol.25.022106.141548 · DOI · Paper page
- Kamimura, 2007, Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo, J Exp Med, 204, 1803, 10.1084/jem.20070543 · DOI
- Boeckh, 2003, Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity, Blood, 101, 407, 10.1182/blood-2002-03-0993 · DOI · Paper page
- Bonini, 2001, Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells, J Immunol, 166, 5250, 10.4049/jimmunol.166.8.5250 · DOI · Paper page
- Hakki, 2003, Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation, Blood, 102, 3060, 10.1182/blood-2002-11-3472 · DOI · Paper page
- Alves, 2003, IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro, Blood, 102, 2541, 10.1182/blood-2003-01-0183 · DOI · Paper page
- Geginat, 2003, Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines, Blood, 101, 4260, 10.1182/blood-2002-11-3577 · DOI · Paper page
- Hislop, 2002, Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection, J Exp Med, 195, 893, 10.1084/jem.20011692 · DOI · Paper page
- McGill, 2010, IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection, J Exp Med, 207, 521, 10.1084/jem.20091711 · DOI · Paper page
- Steel, 2010, Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help, Cancer Res, 70, 1072, 10.1158/0008-5472.CAN-09-1301 · DOI
- Britten, 2002, The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays, J Immunol Methods, 259, 95, 10.1016/S0022-1759(01)00499-9 · DOI
Cited by
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Dendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2017) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 927
Clinical use of dendritic cells for cancer therapy
Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70585-0 · Cited by 700
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Chung, D. J., Romano, E., Pronschinske, K. B., Shyer, J. A., Mennecozzi, M., Angelo, E. T. S., & Young, J. W. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-166 · Cited by 24
Self-citation
Metadata
- Authors
- Romano, E., Rossi, M., Ratzinger, G., de Cos, M.-A., Chung, D. J., Panageas, K. S., Wolchock, J. D., Houghton, A. N., Chapman, P. B., Heller, G., Yuan, J., & Young, J. W.
- Venue
- Clinical Cancer Research
- Published
- 2011-03-31
- Volume
- 17
- Issue
- 7
- Pages
- 1984-1997
- ISSN
- 1078-0432
- 1557-3265
- Cited by
- 75
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro , Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-3421
- The paper
- Romano, E., Rossi, M., Ratzinger, G., de Cos, M.-A., Chung, D. J., Panageas, K. S., Wolchock, J. D., Houghton, A. N., Chapman, P. B., Heller, G., Yuan, J., & Young, J. W. (2011). Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro , Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-3421
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.